These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 12356843

  • 1. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy.
    Mandava N, Blackburn P, Paul DB, Wilson MW, Read SB, Alspaugh E, Tritz R, Barber JR, Robbins JM, Kruse CA.
    Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3338-48. PubMed ID: 12356843
    [Abstract] [Full Text] [Related]

  • 2. HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR.
    Liou GI, Pakalnis VA, Matragoon S, Samuel S, Behzadian MA, Baker J, Khalil IE, Roon P, Caldwell RB, Hunt RC, Marcus DM.
    Mol Vis; 2002 Dec 20; 8():494-501. PubMed ID: 12500176
    [Abstract] [Full Text] [Related]

  • 3. Antisense oligonucleotide targeting c-fos mRNA limits retinal pigment epithelial cell proliferation: a key step in the progression of proliferative vitreoretinopathy.
    Zhang L, Li X, Zhao M, He P, Yu W, Dong J, Liu G, Li C, Shi X.
    Exp Eye Res; 2006 Dec 20; 83(6):1405-11. PubMed ID: 16973160
    [Abstract] [Full Text] [Related]

  • 4. A new model of proliferative vitreoretinopathy.
    Frenzel EM, Neely KA, Walsh AW, Cameron JD, Gregerson DS.
    Invest Ophthalmol Vis Sci; 1998 Oct 20; 39(11):2157-64. PubMed ID: 9761295
    [Abstract] [Full Text] [Related]

  • 5. Targeting of integrin-linked kinase with a small interfering RNA suppresses progression of experimental proliferative vitreoretinopathy.
    Guo L, Yu W, Li X, Zhao G, Liang J, He P, Wang K, Zhou P, Jiang Y, Zhao M.
    Exp Eye Res; 2008 Dec 20; 87(6):551-60. PubMed ID: 18926819
    [Abstract] [Full Text] [Related]

  • 6. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.
    Berger AS, Cheng CK, Pearson PA, Ashton P, Crooks PA, Cynkowski T, Cynkowska G, Jaffe GJ.
    Invest Ophthalmol Vis Sci; 1996 Oct 20; 37(11):2318-25. PubMed ID: 8843916
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy.
    Nakagawa M, Refojo MF, Marin JF, Doi M, Tolentino FI.
    Invest Ophthalmol Vis Sci; 1995 Nov 20; 36(12):2388-95. PubMed ID: 7591628
    [Abstract] [Full Text] [Related]

  • 9. Apoptosis and cell proliferation in proliferative retinal disorders: PCNA, Ki-67, caspase-3, and PARP expression.
    Zhang X, Barile G, Chang S, Hays A, Pachydaki S, Schiff W, Sparrow J.
    Curr Eye Res; 2005 May 20; 30(5):395-403. PubMed ID: 16020270
    [Abstract] [Full Text] [Related]

  • 10. Pathogenesis of proliferative vitreoretinopathy. Modulation of retinal pigment epithelial cell functions by vitreous and macrophages.
    Kirchhof B, Sorgente N.
    Dev Ophthalmol; 1989 May 20; 16():1-53. PubMed ID: 2676632
    [Abstract] [Full Text] [Related]

  • 11. Effect of Robo1 on retinal pigment epithelial cells and experimental proliferative vitreoretinopathy.
    Huang L, Xu Y, Yu W, Li Y, Chu L, Dong J, Li X.
    Invest Ophthalmol Vis Sci; 2010 Jun 20; 51(6):3193-204. PubMed ID: 20071679
    [Abstract] [Full Text] [Related]

  • 12. Retrovirus-mediated suicide gene transduction in the vitreous cavity of the eye: feasibility in prevention of proliferative vitreoretinopathy.
    Kimura H, Sakamoto T, Cardillo JA, Spee C, Hinton DR, Gordon EM, Anderson WF, Ryan SJ.
    Hum Gene Ther; 1996 May 01; 7(7):799-808. PubMed ID: 8860832
    [Abstract] [Full Text] [Related]

  • 13. Attenuated glial reaction in experimental proliferative vitreoretinopathy treated with liposomal doxorubicin.
    Kuo HK, Chen YH, Wu PC, Wu YC, Huang F, Kuo CW, Lo LH, Shiea J.
    Invest Ophthalmol Vis Sci; 2012 Jun 29; 53(6):3167-74. PubMed ID: 22491400
    [Abstract] [Full Text] [Related]

  • 14. Immunoreactive ET-1 in the vitreous humor and epiretinal membranes of patients with proliferative vitreoretinopathy.
    Roldán-Pallarés M, Rollín R, Mediero A, Martínez-Montero JC, Fernández-Cruz A, Bravo-Llata C, Fernández-Durango R.
    Mol Vis; 2005 Jul 07; 11():461-71. PubMed ID: 16030497
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Efficacy and toxicity in the rabbit eye.
    Steinhorst UH, Chen EP, Hatchell DL, Samsa GP, Saloupis PT, Westendorf J, Machemer R.
    Invest Ophthalmol Vis Sci; 1993 Apr 07; 34(5):1753-60. PubMed ID: 8473115
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.